Cayman Leflunomide-d4

Leflunomide-d₄ is intended for use as an internal standard for the quantification of leflunomide (Item No. ) by GC- or LC-MS. Leflunomide is a synthetic isoxazol and a prodrug form of A-771726 (Item No. ), a dihydroorotate dehydrogenase inhibitor. Leflunomide inhibits de novo pyrimidine synthesis to regulate T lymphocyte progression through the cell cycle. It inhibits proliferation and activation of T cells when used at concentrations of 25 and 100 µM, respectively, for naïve and memory CD4⁺ T cells. It also reduces the production of Th1 effector cells and increases differentiation of Th2 cells in vitro and in splenocytes isolated from KLH-immunized mice. Leflunomide (35 mg/kg per day) reduces and prevents inflammation in a proteoglycan-induced mouse model of rheumatoid arthritis. Formulations containing leflunomide have been used in the treatment of active rheumatoid arthritis.

WARNING This product is not for human or veterinary use.